Yigal Nochomovitz is ranked #2489 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Yigal Nochomovitz (Citi) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Yigal Nochomovitz's stock ratings?

About 38% of Yigal's ratings were profitable over a one-year hold, with an average return of -10.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Yigal Nochomovitz

Citi

Yigal Nochomovitz

Citi

Wall Street Analyst

★☆☆☆☆

#2489

on 13Foresight · ranked by our own returns

38%

Success Rate

-10.5%

Average Return

25 of 65 calls profitable · -16.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 38% of Yigal Nochomovitz's ratings turned a profit when each position was held for 1 year — averaging -10.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

210 Buy 14 Hold 12 Sell

Yigal's Stock Coverage 64 ratings · 2026-06-18

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
NBIX Neurocrine	Jun 15, 2026	BUY	Strong Buy +8.0% avg upside 37 analysts	$246.00 56.82% Upside	·
TVTX Travere Therapeutics	Jun 14, 2026	BUY	Strong Buy -14.7% avg upside 22 analysts	$70.00 28.79% Upside	·
MIRM Mirum Pharmaceuticals	Jun 14, 2026	BUY	Strong Buy +10.1% avg upside 21 analysts	$145.00 36.92% Upside	+6.1%
ONC BeOne Medicines	Jun 12, 2026	BUY	Strong Buy +31.0% avg upside 28 analysts	$453.00 67.58% Upside	-0.7%
BMEA Biomea Fusion	Jun 11, 2026	BUY	Strong Buy +1020.0% avg upside 15 analysts	$7.00 493.16% Upside	·
CRBU Caribou Biosciences	Jun 11, 2026	BUY	Strong Buy +585.9% avg upside 12 analysts	$8.00 404.81% Upside	·
STTK Shattuck Labs	Jun 09, 2026	BUY	Strong Buy +387.3% avg upside 14 analysts	$18.00 271.08% Upside	+1.4%
SPTX Seaport Therapeutics, Inc.	Jun 08, 2026	BUY	Strong Buy +103.6% avg upside 4 analysts	$35.00 101.70% Upside	·
SLDB Solid Biosciences	Jun 04, 2026	BUY	Strong Buy +112.8% avg upside 23 analysts	$14.00 77.98% Upside	·
AVBP ArriVent BioPharma, Inc.	Jun 03, 2026	BUY	Strong Buy +38.0% avg upside 15 analysts	$43.00 36.09% Upside	+5.3%
OLMA Olema Pharmaceuticals	May 31, 2026	BUY	Strong Buy +309.3% avg upside 16 analysts	$62.00 572.54% Upside	-27.7%
SMMT Summit Therapeutics	May 31, 2026	BUY	Strong Buy +109.1% avg upside 27 analysts	$40.00 190.68% Upside	-11.7%
KRRO Korro Bio	May 18, 2026	BUY	Strong Buy +133.8% avg upside 19 analysts	$21.00 62.41% Upside	+10.8%
LENZ LENZ Therapeutics	May 13, 2026	BUY	Buy +280.4% avg upside 17 analysts	$20.00 238.35% Upside	-15.2%
ZBIO Zenas BioPharma, Inc.	May 13, 2026	BUY	Strong Buy +110.8% avg upside 11 analysts	$41.00 113.09% Upside	-8.7%
RIGL Rigel	May 13, 2026	BUY	Strong Buy -28.0% avg upside 17 analysts	$81.00 146.36% Upside	+1.8%
LXRX Lexicon Pharmaceuticals	May 11, 2026	BUY	Buy +98.8% avg upside 9 analysts	$3.10 54.58% Upside	-17.3%
ACAD ACADIA Pharmaceuticals	May 08, 2026	BUY	Strong Buy +66.6% avg upside 42 analysts	$32.00 48.40% Upside	-3.6%
ZYME Zymeworks	May 08, 2026	BUY	Strong Buy +39.8% avg upside 25 analysts	$35.00 52.55% Upside	-5.9%
ZLAB Zai Lab	May 08, 2026	BUY	Strong Buy +226.5% avg upside 13 analysts	$44.00 138.21% Upside	-8.2%
CRSP Crispr Therapeutics AG	May 06, 2026	BUY	Buy +41.5% avg upside 41 analysts	$82.00 53.50% Upside	-5.6%
SRPT Sarepta Therapeutics	May 06, 2026	SELL	Buy +251.8% avg upside 49 analysts	$13.00 26.58% Downside	+31.6%
RARE Ultragenyx Pharmaceutical	May 05, 2026	BUY	Strong Buy +144.1% avg upside 36 analysts	$45.00 61.81% Upside	-7.6%
ORIC Oric Pharmaceuticals	May 05, 2026	BUY	Strong Buy +176.0% avg upside 19 analysts	$16.00 86.21% Upside	-13.6%
KRYS Krystal Biotech	May 05, 2026	BUY	Strong Buy -27.6% avg upside 19 analysts	$378.00 8.87% Upside	+20.1%
ARVN Arvinas Holding Company	May 01, 2026	BUY	Buy +266.4% avg upside 27 analysts	$24.00 217.92% Upside	-27.9%
LGND Ligand Pharma	Apr 15, 2026	BUY	Strong Buy -18.2% avg upside 15 analysts	$282.00 3.97% Upside	+16.9%
IDYA IDEAYA Biosciences	Apr 13, 2026	BUY	Strong Buy +55.3% avg upside 29 analysts	$65.00 108.98% Upside	-7.3%
CADL Candel Therapeutics	Mar 18, 2026	BUY	Strong Buy +120.0% avg upside 10 analysts	$26.00 220.11% Upside	+73.1%
DRTS Alpha Tau Medical Ltd	Mar 10, 2026	BUY	Strong Buy +43.6% avg upside 5 analysts	$9.00 6.31% Downside	+37.2%
SGP SpyGlass Pharma	Mar 09, 2026	BUY	Strong Buy +144.6% avg upside 5 analysts	$42.00 128.62% Upside	-31.1%
EYPT EyePoint Pharmaceuticals	Mar 09, 2026	BUY	Strong Buy +129.0% avg upside 17 analysts	$35.00 162.55% Upside	-16.1%
RCUS Arcus Biosciences	Mar 05, 2026	BUY	Strong Buy +39.2% avg upside 20 analysts	$45.00 87.00% Upside	+8.8%
ARCT Arcturus Therapeutics	Mar 04, 2026	HOLD	Buy +298.1% avg upside 35 analysts	$8.00 7.01% Upside	+10.8%
SNDX Syndax Pharmaceuticals	Mar 02, 2026	BUY	Strong Buy +87.3% avg upside 27 analysts	$57.00 195.92% Upside	-17.2%
ARDX Ardelyx	Jan 08, 2026	BUY	Strong Buy +132.3% avg upside 21 analysts	$14.00 137.45% Upside	-20.9%
PROK ProKidney	Sep 03, 2025	BUY	Buy +274.8% avg upside 12 analysts	$10.00 464.88% Upside	-22.9%
PRQR ProQR	Mar 07, 2025	BUY	Strong Buy +572.0% avg upside 18 analysts	$4.00 118.03% Upside	-6.8%
CLLS Cellectis SA	Dec 11, 2024	BUY	Strong Buy +551.9% avg upside 16 analysts	$11.00 254.86% Upside	+174.7%
CHRS Coherus Biosciences	Dec 04, 2024	BUY	Buy +798.0% avg upside 18 analysts	$8.00 467.39% Upside	-28.1%
OPTEY Opthea Limited Sponsored ADR	Sep 12, 2024	BUY	Hold +37096.4% avg upside 7 analysts	$10.00 49651.30% Upside	·
MGNX MacroGenics	Aug 15, 2024	BUY	Buy +341.3% avg upside 25 analysts	$14.00 246.60% Upside	-51.5%
OVID Ovid Therapeutics	Jun 17, 2024	HOLD	Strong Buy +98.5% avg upside 17 analysts	$1.20 48.34% Downside	-61.8%
FATE Fate Therapeutics	May 15, 2024	BUY	Buy +512.6% avg upside 31 analysts	$10.00 407.58% Upside	-76.2%
ALDX Aldeyra Therapeutics	Dec 04, 2023	BUY	Strong Buy +753.6% avg upside 21 analysts	$8.00 316.59% Upside	+51.7%
ATRA Atara Biotherapeutics	Nov 22, 2023	SELL	Buy +86.0% avg upside 18 analysts	$10.00 0.29% Upside	+19.8%
IPHA Innate Pharma	Sep 18, 2023	BUY	Strong Buy +267.3% avg upside 10 analysts	$8.00 346.86% Upside	-18.2%
GRTX Galera Therapeutics	Aug 29, 2023	HOLD	Buy +6797.5% avg upside 7 analysts	$0.25 193.87% Upside	·
PTCT PTC Therapeutics	May 24, 2023	BUY	Strong Buy -1.0% avg upside 29 analysts	$63.00 20.15% Downside	-20.8%
NCNA Nucana	Nov 28, 2022	BUY	Strong Buy +573.3% avg upside 9 analysts	$2.00 6.46% Upside	-48.9%
FR:IPH Innate Pharma SA	Sep 16, 2022	BUY	Strong Buy +453.3% avg upside 5 analysts	$12.00 650.87% Upside	·
ELVN Enliven Therapeutics	Apr 05, 2022	HOLD	Strong Buy +7.6% avg upside 14 analysts	$8.00 82.15% Downside	+5.8%
PBYI Puma Biotechnology	Sep 27, 2021	BUY	Buy +480.9% avg upside 11 analysts	$11.00 49.11% Upside	-68.1%
SYBX Synlogic	Aug 21, 2019	SELL	Buy +3290.3% avg upside 11 analysts	$2.00 181.60% Upside	+31.3%
AKBA Akebia Therapeutics	Mar 20, 2019	HOLD	Strong Buy +864.1% avg upside 16 analysts	$9.00 782.34% Upside	-32.2%
ANTH Anthera Pharmaceuticals	Dec 29, 2016	HOLD	Buy +472857042.9% avg upside 9 analysts	—	·
NTBLQ Notable Labs	Aug 13, 2015	HOLD	Buy +809999900.0% avg upside 12 analysts	—	·
VSTM Verastem	Apr 27, 2015	HOLD	Strong Buy +254.8% avg upside 23 analysts	—	-82.5%
ENLV Enlivex	Mar 31, 2015	BUY	Strong Buy +3482.1% avg upside 4 analysts	$32.00 5095.58% Upside	-58.5%
OCUL Ocular Therapeutix	Mar 30, 2015	BUY	Strong Buy +153.7% avg upside 21 analysts	$49.00 415.80% Upside	-78.0%
KPTI Karyopharm Therapeutics	Mar 16, 2015	BUY	Strong Buy +139.5% avg upside 18 analysts	$53.00 487.63% Upside	-75.6%
LSTA Lisata Therapeutics	Jan 09, 2015	BUY	Buy +266.9% avg upside 11 analysts	$10.00 185.63% Upside	-86.6%
SLS SELLAS Life Sciences Group	Nov 23, 2014	HOLD	Strong Buy +799.8% avg upside 15 analysts	—	-21.2%
IL:KMDA Kamada	Nov 21, 2014	HOLD	Strong Buy +72.4% avg upside 7 analysts	—	·

🔒 59 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Yigal Nochomovitz — Frequently Asked Questions

How accurate are Yigal Nochomovitz's stock ratings?

Based on the calls 13Foresight could measure, about 38% of Yigal's ratings were profitable over a one-year hold, with an average return of -10.6% per rating, or -16.4% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Yigal ranked on 13Foresight?

Yigal Nochomovitz is currently ranked #2489 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Yigal cover?

Yigal most recently has ratings on NBIX, TVTX, MIRM, ONC, BMEA, CRBU, STTK, SPTX, SLDB, AVBP, OLMA, SMMT and 52 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!